The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Padviram 600 mg/200 mg/245 mg film-coated tablets

600mg/200mg/245 milligram(s) Film-coated tablet

Rowex LtdPA0711/277/001

Main Information

Trade NamePadviram 600 mg/200 mg/245 mg film-coated tablets
Active SubstancesEfavirenz
Tenofovir disoproxil
Strength600mg/200mg/245 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/277/001

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR06 emtricitabine, tenofovir disoproxil and efavirenz


Licence Issued20/10/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceConditions None. Commitments Will not market until July 2018 (due to product name issue).
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back